Prevalence of KRAS G12C Mutations Across Different Populations

<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we'll discuss the findings of a study that examined the prevalence of <i>KRAS</i> G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.</p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">Prevalence of </a><i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">KRAS </a></i><a href=\"https://ascopost.com/news/january-2021/prevalence-of-kras-g12c-somatic-mutations-by-cancer-type-race-and-sex/\" target=\"_blank\">G12C Somatic Mutations by Cancer Type, Race, and Sex</a></p><p><a href=\"https://ascopost.com/issues/january-25-2021/fda-approves-crizotinib-for-children-and-young-adults-with-relapsed-or-refractory-s...